治験レーダーAI | ||
|---|---|---|
治験 NCT07494409（対象：Anemia Due to Chronic Kidney Disease）は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia 第III相・フェーズ3 300 無作為化 非盲検
治験（臨床試験）の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします！「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT07494409 は Anemia Due to Chronic Kidney Disease に関する 治療 の研究で、第III相・フェーズ3 介入研究 臨床試験 です。現在は 募集中 で、2025年10月31日 から開始しています。300 名の参加者 の募集が計画されています。この試験は Kind Pharmaceuticals LLC によって主導され、2027年4月30日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2026年3月27日 です。
概要
This is a phase III, randomized, open-label, active-controlled study to evaluate the safety and efficacy of AND017 in anemic patients with End-Stage-Kidney-Disease (ESKD)
公式タイトル
A Phase 3, Multi-center, Randomized, Open-Label, Active-Controlled, Efficacy and Safety Study of AND017 to Treat Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia
疾患名
Anemia Due to Chronic Kidney Diseaseその他の研究識別子
- AND017-CN-302
- CTR20253615 (その他の識別子) (China National Medical Products Administration)
NCT番号
開始日
2025-10-31
最終更新日
2026-03-27
終了予定日
2027-04-30
目標参加者数
300
試験の種類
介入研究
治験の相・段階
第III相・フェーズ3
状況
募集中
キーワード
anemia
CKD
ESKD
CKD
ESKD
主目的
治療
割付方法
無作為化
介入モデル
並行割当
盲検化
なし（非盲検）
群（アーム）／介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
実験的AND017 | AND017 capsules AND017 capsules administered orally with a starting dose of 10 mg TIW |
実薬対照薬Erythropoiesis Stimulating Agents (ESA) | ESA ESA injection and dose based on package insert and local practice |
主要評価項目
副次評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Evaluate the efficacy of AND017 compared with the active control in maintaining Hb levels in anemic patients with ESKD | The mean Hb levels averaged over Week 23-27 | From Week 23 to Week 27 |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
The percentage of responders | Responder is defined as: for participants with baseline Hb ≥ 9.0 g/dL, mean Hb ≥10.0 g/dL and a change from baseline ≥ -1.0 g/dL during Weeks 23-27 | From baseline to Week 27 |
Percentage of participants that maintained Hb level over target lower limit | Percentage of participants with mean Hb ≥ 10.0 g/dL averaged over Weeks 5-27 | From Week 5 to Week 27 |
Maintenance of Hb within 10.0-12.0 g/dL after initial achievement ≥10.0 g/dL during the entire study treatment period. | During entire study treatment period, the percentage of participants in which Hb, after first reaching ≥ 10.0 g/dL, is maintained within the target range of 10.0-12.0 g/dL (inclusive) | From baseline to Week 53 |
Incidence of extreme Hb levels of ≥13.0 g/dL or <7.5 g/dL during the entire study treatment period | During the entire study treatment period, the percentage of participants in which Hb is ≥ 13.0 g/dL or \< 7.5 g/dL | From baseline to Week 53 |
Incidence of excessive erythropoiesis | During the entire study treatment period, the percentage of participants with an Hb increase ≥ 1.0 g/dL within any 2-week period and an Hb increase ≥ 2.0 g/dL within any 4-week period respectively | From baseline to Week 53 |
The cumulative incidence of Hb non-response | The cumulative incidence of Hb non-response is defined as Hb \< 10.0 g/dL and an increase from baseline \< 1.0 g/dL averaged over Weeks 5-27 | From baseline to Week 27 |
Mean Hb change from baseline averaged over Weeks 5-27 | Mean Hb change from baseline averaged over Weeks 5-27 | From baseline to Week 27 |
Mean Hb change from baseline averaged over Weeks 23-27 | Mean Hb change from baseline averaged over Weeks 23-27 | From baseline to Week 27 |
Mean Hb change from baseline averaged over Weeks 13-17 | Mean Hb change from baseline averaged over Weeks 13-17 | From baseline to Week 17 |
Mean Hb change from baseline averaged over Weeks 27-53 | Mean Hb change from baseline averaged over Weeks 27-53 | From baseline to Week 53 |
Mean Hb change from baseline averaged over Weeks 49-53 | Mean Hb change from baseline averaged over Weeks 49-53 | Mean Hb change from baseline averaged over Weeks 49-53 |
During the entire treatment period, mean Hb at each visit | During the entire treatment period, mean Hb at each visit | From baseline to Week 53 |
The use of intravenous iron during the entire study treatment period | The percentage of participants that have received intravenous iron during the entire study treatment period | From baseline to Week 53 |
The mean weekly dose of intravenous iron during the entire treatment period | The mean weekly dose of intravenous iron during the entire treatment period | From baseline to Week 53 |
The time to first initiation of intravenous iron during the entire treatment period | The time to first initiation of intravenous iron during the entire treatment period | From baseline to Week 53 |
参加アシスタント
適格基準
対象年齢
成人, 高齢者
試験の最低年齢
18 Years
対象性別
全て
- Receiving stable hemodialysis (including combination methods such as hemodiafiltration or hemofiltration), peritoneal dialysis for ESKD for a minimum of 16 weeks prior to randomization and determined by the Investigator to be compliant with dialysis treatment prescription.
- Patient must have been on IV or SC of an approved ESA under the prescription for at least 6 weeks
- The mean of two hemoglobin values during screening must be 9.0-12.0 g/dL.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)<3× upper limit of normal (ULN)
- Transferrin saturation ≥20% or ferritin ≥100 ng/mL at screening test
- Serum folate and vitamin B12 ≥ lower limit of normal (LLN) at screening test
- Concurrent retinal neovascular lesions requiring treatment
- Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis or concurrent autoimmune disease with inflammatory symptoms
- History of gastric/intestinal resection considered to affect the absorption of drugs in the gastrointestinal tract or concurrent symptomatic gastroparesis despite being on treatment
- Uncontrolled hypertension, defined as patients with hypertension having more than one of three systolic blood pressure >180 mmHg, or diastolic blood pressure >110 mmHg during the screening assessment
- Concurrent congestive heart failure (New York Heart Association \[NYHA\] Class III or higher)
- History of stroke, transient ischemic attack (TIA), myocardial infarction, thromboembolic event (deep vein thrombosis, DVT), pulmonary embolism, or lung infarction within 24 weeks before the screening assessment
- Participants with a history of significant liver disease or active liver disease
- History of a seizure disorder or any occurrence of seizures in the past
- Serum albumin (ALB) < 2.5 g/dL at screening test
- Prior ESA/hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) treatment caused total bilirubin >1.5xULN, or AST/ALT/ ALP>3xULN, or serious liver disease (acute or active chronic hepatitis, cirrhosis, etc.)
- Any prior functioning organ transplant or a scheduled organ transplantation, or anephric
Kind Pharmaceuticals LLC試験中央連絡先
連絡先: Yusha Zhu, MD, PhD, 6467252552, [email protected]
1 1カ国の場所
Fudan Univeristy Zhongshan Hospital, Shanghai, 200032, China
Xiaoqiang Ding, 主任研究者
募集中